Ocular Therapeutix (OCUL) Reports First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for Treatment of Dry Eye Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. HOOD
10. MSTR

Go back to Ocular Therapeutix (OCUL) Reports First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for Treatment of Dry Eye Disease

Ocular Therapeutix (OCUL) Misses Q1 EPS by 4c, Revenues Miss

May 8, 2020 7:09 AM EDT

Ocular Therapeutix (NASDAQ: OCUL) reported Q1 EPS of ($0.41), $0.04 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $2.61 million versus the consensus estimate of $2.84 million.

The outlook for Ocular continues to brighten, said Antony Mattessich, President and CEO. As our... More